Reuters logo
BRIEF-Ionis Pharma announces Phase 3 NEURO-TTR study of inotersen meets both primary endpoints
May 15, 2017 / 11:25 AM / 7 months ago

BRIEF-Ionis Pharma announces Phase 3 NEURO-TTR study of inotersen meets both primary endpoints

May 15 (Reuters) - Ionis Pharmaceuticals Inc

* Ionis pharmaceuticals announces phase 3 neuro-ttr study of inotersen (ionis-ttr rx) meets both primary endpoints

* Says statistically significant differences were also observed for both endpoints at eight months

* Ionis pharmaceuticals - long-term safety and efficacy data with inotersen currently being collected in open-label extension of phase 3 neuro-ttr study

* Says review of full data package from neuro-ttr study by ionis and gsk is ongoing

* Says preparation of regulatory marketing applications for inotersen is underway

* Ionis pharmaceuticals - gsk has option to license inotersen following review of additional data and prior to submission of regulatory applications Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below